NCT01778439View on ClinicalTrials.gov

A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
Relapsed or Refractory Solid Tumors
Interventions
DRUG

OMP-52M51

Trial Locations (6)

48201

Karmanos Cancer Institute (KCI), Detroit

Wayne State University/Oncology Karmanos Cancer Institute, Detroit

77030

The University of Texas MD Anderson Cancer Center, Houston

78229

South Texas Accelerated Research Therapeutics, LLC, San Antonio

80045

University of Colorado Denver -RCI-South Tower, Aurora

94115

University of California, San Francisco/Helen Diller Cancer Institute, San Francisco

Sponsors
All Listed Sponsors
lead

OncoMed Pharmaceuticals, Inc.

INDUSTRY